Estimaciones de analistas de Wall Street para ADMA Biologics, Inc. (ADMA): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.19 | ||
| 2026-08-05 | $0.16 | $0.16 | -2.0% |
| 2026-05-06 | $0.19 | $0.19 | -1.7% |
| 2026-02-25 | $0.20 | $0.18 | +8.1% |
| 2025-11-05 | $0.16 | $0.16 | +0.0% |
| 2025-08-06 | $0.15 | $0.14 | +7.1% |
| 2025-05-07 | $0.14 | $0.16 | -12.5% |
| 2025-03-03 | $0.14 | $0.15 | -6.7% |
Ratios de valoración
| Ratio P/E | 12.55 |
| Precio / Valor contable | 5.05 |
| EV / EBITDA | 21.93 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $10.7M | $22.8M | $17.0M | $29.3M | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Coste de Ventas | $6.4M | $29.2M | $42.2M | $39.5M | $61.3M | $79.8M | $118.8M | $169.3M | $206.9M | $217.4M |
| Beneficio Bruto | $4.3M | -$6.4M | -$25.2M | -$10.2M | -$19.1M | $1.2M | $35.3M | $88.9M | $219.6M | $292.8M |
| I+D | $7.7M | $6.2M | $3.9M | $2.3M | $5.9M | $3.6M | $3.6M | $3.3M | $1.8M | $4.8M |
| Generales y Administrativos | $8.5M | $18.1M | $22.5M | $25.9M | $35.1M | $42.9M | $52.5M | $59.0M | $74.1M | $91.6M |
| Gastos Operativos | $21.6M | $32.1M | $35.1M | $31.3M | $45.8M | $59.5M | $74.6M | $67.3M | $80.6M | $101.3M |
| Beneficio Operativo | -$17.3M | -$39.3M | -$60.3M | -$41.4M | -$64.9M | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| EBITDA | -$16.8M | -$39.3M | -$56.8M | -$36.0M | -$59.8M | -$53.1M | -$39.5M | $5.1M | $147.7M | $197.9M |
| Gastos por Intereses | $2.2M | $3.3M | $5.5M | $9.0M | $12.0M | $13.1M | $19.3M | $25.0M | $13.9M | $7.1M |
| Beneficio Antes de Impuestos | -$19.5M | -$43.8M | -$65.7M | -$48.3M | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $125.7M | $182.7M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$72.0M | $35.7M |
| Beneficio Neto | -$19.5M | -$43.8M | -$65.7M | -$48.3M | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| BPA | $-1.61 | $-1.91 | $-1.45 | $-1.05 | $-1.02 | $-0.61 | $-0.43 | $-0.13 | $0.85 | $0.62 |
| BPA Diluido | $-1.61 | $-1.91 | $-1.45 | $-1.05 | $-1.02 | $-0.61 | $-0.43 | $-0.13 | $0.81 | $0.60 |
| Acciones en Circulación (Diluidas) | $12.2M | $22.9M | $45.2M | $54.3M | $86.1M | $139.6M | $197.9M | $224.0M | $243.3M | $244.9M |
Precio
| Precio | $8.90 |
| Capitalización | $2.1B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACAD · BLTE · CRNX · DYN · LGND · MIRM · PRAX
Explorar sector: Healthcare · Biotechnology
Más secciones de ADMA: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones